These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22364143)

  • 1. U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes.
    Lowery JB; Donihi AC; Korytkowski MT
    Diabetes Technol Ther; 2012 Jun; 14(6):505-7. PubMed ID: 22364143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance.
    Lane WS; Weinrib SL; Rappaport JM; Przestrzelski T
    Endocr Pract; 2010; 16(5):778-84. PubMed ID: 20350913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin.
    Hopton OM; Waterbury NV; Egge JA; Lund BC
    Pharmacotherapy; 2022 Jan; 42(1):45-52. PubMed ID: 34807465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
    Buse JB; Wolffenbuttel BH; Herman WH; Shemonsky NK; Jiang HH; Fahrbach JL; Scism-Bacon JL; Martin SA
    Diabetes Care; 2009 Jun; 32(6):1007-13. PubMed ID: 19336625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients.
    Ziesmer AE; Kelly KC; Guerra PA; George KG; Dunn FL
    Endocr Pract; 2012; 18(1):34-8. PubMed ID: 21742613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis.
    Sutton D; Higdon CD; Nikkel C; Hilsinger KA
    Adv Ther; 2018 May; 35(5):631-643. PubMed ID: 29748915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin requirement profiles of patients with type 2 diabetes after achieving stabilized glycemic control with short-term continuous subcutaneous insulin infusion.
    Noh YH; Lee WJ; Kim KA; Lim I; Lee JH; Lee JH; Kim S; Choi SB
    Diabetes Technol Ther; 2010 Apr; 12(4):271-81. PubMed ID: 20210565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved A1C by switching to continuous subcutaneous insulin infusion from injection insulin therapy in type 2 diabetes: A retrospective claims analysis.
    Lynch P; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
    Prim Care Diabetes; 2010 Dec; 4(4):209-14. PubMed ID: 20832374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen® among US veterans with type 2 diabetes mellitus.
    Chen J; Borra S; Fan L; Huang A; Patel D; Juneja R
    J Diabetes Complications; 2021 Oct; 35(10):107995. PubMed ID: 34364779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine.
    Bergenstal RM; Johnson M; Powers MA; Wynne A; Vlajnic A; Hollander P; Rendell M
    Diabetes Care; 2008 Jul; 31(7):1305-10. PubMed ID: 18364392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes.
    Shanik MH
    Diabetes Technol Ther; 2012 Jun; 14(6):533-9. PubMed ID: 22364142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
    Takahara M; Shiraiwa T; Katakami N; Matsuoka TA; Shimomura I
    Diabetes Technol Ther; 2014 Oct; 16(10):633-9. PubMed ID: 24949654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
    Khunti K; Caputo S; Damci T; Dzida GJ; Ji Q; Kaiser M; Karnieli E; Liebl A; Ligthelm RJ; Nazeri A; Orozco-Beltran D; Pan C; Ross SA; Svendsen AL; Vora J; Yale JF; Meneghini LF;
    Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with U500 insulin: risks and benefits.
    Boldo A; Comi RJ
    Endocr Pract; 2012; 18(1):56-61. PubMed ID: 21803710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy.
    Shimoda S; Okubo M; Koga K; Sekigami T; Kawashima J; Kukidome D; Igata M; Ishii N; Shimakawa A; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2015; 62(2):209-16. PubMed ID: 25392020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
    Riddle MC; Rosenstock J; Vlajnic A; Gao L
    Diabetes Obes Metab; 2014 May; 16(5):396-402. PubMed ID: 24118931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
    Dailey G; Admane K; Mercier F; Owens D
    Diabetes Technol Ther; 2010 Dec; 12(12):1019-27. PubMed ID: 21128849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.